Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mariam Naveed

Gastroenterology Altamonte Springs, FL Medical Doctor

NPI 1477797371 CMS profile 1368911

661 E Altamonte Dr Ste 216, Altamonte Springs, FL 32701

Open in the dashboard

General payments

$21,899

80 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mariam Naveed of Altamonte Springs, FL is reported in the CMS Open Payments database as having received $21,899 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,489 29
2024 General $11,907 32
2023 General $769 12
2022 General $489 5
2021 General $245 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mariam Naveed
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Mariam Naveed were reported at $8,489. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Mariam Naveed Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $245 $352 $106–$1,054 $132
2022 $489 $448 $129–$1,270 $149
2023 $769 $533 $150–$1,390 $160
2024 $11,907 $605 $160–$1,606 $164
2025 $8,489 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $11,111 16 payments
  2. Olympus America Inc. $7,903 5 payments
  3. AbbVie, Inc. $916 28 payments
  4. Janssen Scientific Affairs, LLC $252 2 payments
  5. Cook Medical LLC $229 5 payments
  6. Boston Scientific Corporation $220 4 payments
  7. Janssen Biotech, Inc. $184 2 payments
  8. Medtronic, Inc. $171 2 payments
  9. Ferring Pharmaceuticals Inc. $145 2 payments
  10. Regeneron Pharmaceuticals, Inc. $139 1 payment
  11. Other $629 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $9,822 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,903 5 payments
  3. Food and Beverage $3,240 70 payments
  4. Travel and Lodging $876 2 payments
  5. Education $59 1 payment
Products named General payments · program years 2021–2025
  1. EVIS EXERA III COLONOVIDEOSCOPE $7,903 5 payments
  2. GASTROINTESTINAL VIDEOSCOPE $6,365 2 payments
  3. EVIS EXERA III VIDEO SYSTEM CENTER $6,365 2 payments
  4. SKYRIZI $429 13 payments
  5. STELARA $301 3 payments
  6. RINVOQ $300 11 payments
  7. TREMFYA $260 2 payments
  8. DUPIXENT $174 9 payments
  9. HemoSphere $163 3 payments
  10. ProdiGI $150 1 payment
  11. Other $1,430 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

533

Median for Gastroenterology: 569

Drug cost

$795,320

Median for Gastroenterology: $104,976

Branded share of claims

24.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 18 $499,171
Humira(Cf) Pen Adalimumab Brand 20 $215,906
Xifaxan Rifaximin Brand 16 $49,103
Linzess Linaclotide Brand 25 $18,906
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 20 $3,485
Mesalamine Generic 19 $2,826
Pantoprazole Sodium Generic 201 $1,643
Colestipol Hcl Generic 15 $1,189
Omeprazole Generic 74 $801
Sucralfate Generic 31 $581

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$45,474

Medicare's payments for the services billed

Medicare patients

307

Average age 74

Services billed

582

196 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 45%
Chronic kidney disease 40%
Diabetes 37%
Atrial fibrillation 31%
Depression 31%
Cancer 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $191
$191 — —
DUPIXENT
  • GENZYME CORPORATION $67
$67 — —
TREMFYA
  • Janssen Biotech, Inc. $63
$63 — —
STELARA
  • Janssen Biotech, Inc. $63
$63 18 —
ZEPBOUND
  • Lilly USA, LLC $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record